Roche News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

08.12.20	Roche presents new data from its bispecific antibody portfolio across a range of blood cancers (GlobeNewswire)
07.12.20	New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
07.12.20	New follow-up phase III data reinforce the long-term benefit of Roche’s Hemlibra for people with haemophilia A (GlobeNewswire)
05.12.20	Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia (GlobeNewswire)
02.12.20	Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers (GlobeNewswire)
02.12.20	Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies (GlobeNewswire)
01.12.20	FDA approves Xolair® (omalizumab) for adults with nasal polyps (GlobeNewswire)
24.11.20	Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person (GlobeNewswire)
16.11.20	Roche zum elften Mal als nachhaltigstes Gesundheitsunternehmen im Dow Jones Sustainability Index ausgezeichnet (GlobeNewswire)
16.11.20	Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the eleventh time (GlobeNewswire)
13.11.20	CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza (GlobeNewswire)
13.11.20	CHMP recommends EU approval of Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer (GlobeNewswire)
05.11.20	Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting (GlobeNewswire)
02.11.20	European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer (GlobeNewswire)
29.10.20	Roche’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer (GlobeNewswire)
22.10.20	Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients (GlobeNewswire)
19.10.20	Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia (GlobeNewswire)
15.10.20	First nine months of the year with 1% sales growth at constant exchange rates, significant impact of COVID-19 pandemic (GlobeNewswire)
15.10.20	Wachstum von 1% zu konstanten Wechselkursen in den ersten neun Monaten, starker Einfluss der COVID-19-Pandemie (GlobeNewswire)
13.10.20	Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients (GlobeNewswire)
28.09.20	Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA) (GlobeNewswire)
19.09.20	Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020 (GlobeNewswire)
18.09.20	Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer (GlobeNewswire)
18.09.20	Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines (GlobeNewswire)
18.09.20	Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia (GlobeNewswire)
17.09.20	Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020 (GlobeNewswire)
16.09.20	Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer (GlobeNewswire)
11.09.20	New data further reinforce Roche’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis (GlobeNewswire)
10.09.20	New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD) (GlobeNewswire)
09.09.20	Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab) (GlobeNewswire)
08.09.20	Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients (GlobeNewswire)
07.09.20	Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (GlobeNewswire)
04.09.20	Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems (GlobeNewswire)
03.09.20	Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020 (GlobeNewswire)
01.09.20	Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care (GlobeNewswire)
01.09.20	Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS (GlobeNewswire)
28.08.20	Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test (GlobeNewswire)
19.08.20	Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19 (GlobeNewswire)
17.08.20	FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD) (GlobeNewswire)
10.08.20	FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older (GlobeNewswire)
10.08.20	Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis (GlobeNewswire)
06.08.20	Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer (GlobeNewswire)
05.08.20	Roche announces FDA authorisation for the first Epstein-Barr virus quantitative test on the cobas 6800/8800 Systems to improve care for transplant patients (GlobeNewswire)
03.08.20	Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer (GlobeNewswire)
31.07.20	FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma (GlobeNewswire)
29.07.20	FDA approves Roche’s new VENTANA HER2 Dual ISH test as companion diagnostic to identify breast cancer patients eligible for targeted therapy (GlobeNewswire)
29.07.20	Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia (GlobeNewswire)
23.07.20	First half of the year with 1%1 growth at constant exchange rates, significant impact of COVID-19 pandemic (GlobeNewswire)
23.07.20	Erstes Halbjahr mit 1%1 Wachstum zu konstanten Wechselkursen, starker Einfluss der Covid-19- Pandemie (GlobeNewswire)
22.07.20	Phase III data show Roche’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

17:58		Freundlicher Handel: TecDAX letztendlich im Plus
17:58		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
17:58		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
17:58		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
17:58		SDAX aktuell: SDAX zum Handelsende auf grünem Terrain
17:58		Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen